Frontiers in Immunology (Sep 2023)
Rationale for combined therapies in severe-to-critical COVID-19 patients
- Aitor Gonzaga,
- Aitor Gonzaga,
- Etelvina Andreu,
- Etelvina Andreu,
- Luis M. Hernández-Blasco,
- Rut Meseguer,
- Rut Meseguer,
- Karima Al-Akioui-Sanz,
- Karima Al-Akioui-Sanz,
- Bárbara Soria-Juan,
- Jose Carlos Sanjuan-Gimenez,
- Cristina Ferreras,
- Juan R. Tejedo,
- Juan R. Tejedo,
- Guillermo Lopez-Lluch,
- Rosa Goterris,
- Loreto Maciá,
- Jose M. Sempere-Ortells,
- Jose M. Sempere-Ortells,
- Abdelkrim Hmadcha,
- Abdelkrim Hmadcha,
- Alberto Borobia,
- Jose L. Vicario,
- Ana Bonora,
- Cristobal Aguilar-Gallardo,
- Jose L. Poveda,
- Cristina Arbona,
- Cristina Alenda,
- Fabian Tarín,
- Francisco M. Marco,
- Francisco M. Marco,
- Esperanza Merino,
- Esperanza Merino,
- Esperanza Merino,
- Francisco Jaime,
- José Ferreres,
- Juan Carlos Figueira,
- Carlos Cañada-Illana,
- Sergio Querol,
- Manuel Guerreiro,
- Cristina Eguizabal,
- Cristina Eguizabal,
- Alejandro Martín-Quirós,
- Ángel Robles-Marhuenda,
- Antonio Pérez-Martínez,
- Antonio Pérez-Martínez,
- Carlos Solano,
- Bernat Soria,
- Bernat Soria,
- Bernat Soria
Affiliations
- Aitor Gonzaga
- Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain
- Aitor Gonzaga
- Institute of Bioengineering, Miguel Hernández University, Elche, Spain
- Etelvina Andreu
- Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain
- Etelvina Andreu
- Applied Physics Department, Miguel Hernández University, Elche, Spain
- Luis M. Hernández-Blasco
- Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain
- Rut Meseguer
- Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain
- Rut Meseguer
- Clinic University Hospital, Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana (INCLIVA) Health Research Institute, Valencia, Spain
- Karima Al-Akioui-Sanz
- Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain
- Karima Al-Akioui-Sanz
- Hospital La Paz Institute for Health Research, IdiPAZ, University Hospital La Paz, Madrid, Spain
- Bárbara Soria-Juan
- Réseau Hospitalier Neuchâtelois, Hôpital Pourtalès, Neuchâtel, Switzerland
- Jose Carlos Sanjuan-Gimenez
- Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain
- Cristina Ferreras
- Hospital La Paz Institute for Health Research, IdiPAZ, University Hospital La Paz, Madrid, Spain
- Juan R. Tejedo
- Department of Molecular Biology and Biochemical Engineering, University Pablo de Olavide, Seville, Spain
- Juan R. Tejedo
- Biomedical Research Network for Diabetes and Related Metabolic Diseases-Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) of the Carlos III Health Institute (ISCIII), Madrid, Spain
- Guillermo Lopez-Lluch
- University Pablo de Olavide, Centro Andaluz de Biología del Desarrollo - Consejo Superior de Investigaciones Científicas (CABD-CSIC), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Sevilla, Spain
- Rosa Goterris
- Clinic University Hospital, Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana (INCLIVA) Health Research Institute, Valencia, Spain
- Loreto Maciá
- 0Nursing Department, University of Alicante, Alicante, Spain
- Jose M. Sempere-Ortells
- Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain
- Jose M. Sempere-Ortells
- 1Biotechnology Department, University of Alicante, Alicante, Spain
- Abdelkrim Hmadcha
- Department of Molecular Biology and Biochemical Engineering, University Pablo de Olavide, Seville, Spain
- Abdelkrim Hmadcha
- 2Biosanitary Research Institute (IIB-VIU), Valencian International University (VIU), Valencia, Spain
- Alberto Borobia
- 3Clinical Pharmacology Department, La Paz University Hospital, School of Medicine, Universidad Autónoma de Madrid, IdiPAz, Madrid, Spain
- Jose L. Vicario
- 4Transfusion Center of the Autonomous Community of Madrid, Madrid, Spain
- Ana Bonora
- 5Health Research Institute Hospital La Fe, Valencia, Spain
- Cristobal Aguilar-Gallardo
- 5Health Research Institute Hospital La Fe, Valencia, Spain
- Jose L. Poveda
- 5Health Research Institute Hospital La Fe, Valencia, Spain
- Cristina Arbona
- 6Valencian Community Blood Transfusion Center, Valencia, Spain
- Cristina Alenda
- Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain
- Fabian Tarín
- Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain
- Francisco M. Marco
- Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain
- Francisco M. Marco
- 7Immunology Department, Dr. Balmis General University Hospital, Alicante, Spain
- Esperanza Merino
- Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain
- Esperanza Merino
- 8Department of Clinical Medicine, Miguel Hernández University, Elche, Spain
- Esperanza Merino
- 9Infectious Diseases Unit, Dr. Balmis General University Hospital, Alicante, Spain
- Francisco Jaime
- Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain
- José Ferreres
- 0Intensive Care Service, Hospital Clinico Universitario, Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana (INCLIVA), Valencia, Spain
- Juan Carlos Figueira
- 1Intensive Care Unit, Hospital Universitario La Paz – IdiPAZ, Madrid, Spain
- Carlos Cañada-Illana
- 2Emergency Department, Hospital Universitario La Paz – IdiPAZ, Madrid, Spain
- Sergio Querol
- 3Banc de Sang I Teixits, Barcelona, Spain
- Manuel Guerreiro
- 4Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain
- Cristina Eguizabal
- 5Research Unit, Basque Center for Blood Transfusion and Human Tissues, Galdakao, Spain
- Cristina Eguizabal
- 6Cell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain
- Alejandro Martín-Quirós
- 2Emergency Department, Hospital Universitario La Paz – IdiPAZ, Madrid, Spain
- Ángel Robles-Marhuenda
- 7Internal Medicine Department, Hospital Universitario La Paz – IdiPAZ, Madrid, Spain
- Antonio Pérez-Martínez
- Hospital La Paz Institute for Health Research, IdiPAZ, University Hospital La Paz, Madrid, Spain
- Antonio Pérez-Martínez
- 8Department of Pediatrics, Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
- Carlos Solano
- 9Hematology Service, Hospital Clínico Universitario, Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana (INCLIVA), Valencia, Spain
- Bernat Soria
- Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain
- Bernat Soria
- Institute of Bioengineering, Miguel Hernández University, Elche, Spain
- Bernat Soria
- Biomedical Research Network for Diabetes and Related Metabolic Diseases-Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) of the Carlos III Health Institute (ISCIII), Madrid, Spain
- DOI
- https://doi.org/10.3389/fimmu.2023.1232472
- Journal volume & issue
-
Vol. 14
Abstract
An unprecedented global social and economic impact as well as a significant number of fatalities have been brought on by the coronavirus disease 2019 (COVID-19), produced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute SARS-CoV-2 infection can, in certain situations, cause immunological abnormalities, leading to an anomalous innate and adaptive immune response. While most patients only experience mild symptoms and recover without the need for mechanical ventilation, a substantial percentage of those who are affected develop severe respiratory illness, which can be fatal. The absence of effective therapies when disease progresses to a very severe condition coupled with the incomplete understanding of COVID-19’s pathogenesis triggers the need to develop innovative therapeutic approaches for patients at high risk of mortality. As a result, we investigate the potential contribution of promising combinatorial cell therapy to prevent death in critical patients.
Keywords
